A recent phase II trial suggested that intracarotid infusion of ALD-401 did not lead to adverse events, and the mean difference in recovery favored the treatment group; however, this difference failed to reach statistical significance ( 33 ).
1
—
—
A recent phase II trial suggested that intracarotid infusion of ALD-401 did not lead to adverse events, and the mean difference in recovery favored the treatment group; however, this difference failed to reach statistical significance ( 33 ).